Ann: DyeVert featured at the SCAI 2020 Scientific Session, page-10

First 10 Last

Share
Profile

Follow
gazza01

291 Posts.

22

03/06/20

13:08

Post #: 45008233
Share

Originally posted by tradingformils: ↑

Furthermore to my original post, I have spent time analysing the company today:
- Management own almost no stock - this is a major negative. I also think that the CEO's salary is far too high and its a joke that he hasn't lowered it in the current economic climate.
- Brandon owns 26% of the company (assuming it picks up 20% of the shortfall). If the shortfall is fully subscribed, lets say it owns 16% of the company if it doesn't get any shortfall shares. (See prospectus for rights issue)
- Allan Gray own 13.44%. (8 May announcement)
- I can't see any other funds outside Brandon and Allan Gray??? I found the other 8 May substantial holding exposure confusing since it adds up to 110% of outstanding CDIs. Can somebody offer any further comment?
- Institutional ownership is roughly 40% using my calculations.
- The company's burn rate is close to $5M a quarter. The high cash burn seems to be paying sales people mainly in the US, also the CEO and company offices/ administration. Following the recent raise of $12.5M, it has a bit over two quarters left in the kitty.
- The near term catalyst is possibly the GE Healthcare deal.
- The chart is very poor. However it could be seen as attractive buying territory around these prices since the EV is roughly $6M, ahead of the GE Healthcare deal expected this month.
- I don't really understand the product's benefit as well. Does it save lives?
-Trading For Millions

Expand

I see that they report that office staff took a 20% pay cut - I guess that doesn't apply to the CEO?

OSP Price at posting: 1.4¢ Sentiment: Buy Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

BUX

Buxton projects new graphite province discovery at WA Narryer play

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

There are more pages in this discussion • 22 more messages in this thread...

First 10 Last

Add OSP (ASX) to my watchlist

Ann: DyeVert featured at the SCAI 2020 Scientific Session, page-10

Top Stories

Buxton projects new graphite province discovery at WA Narryer play

BCI reaches close of funding facility for salt-first part of Mardie project

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Featured News